v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Summary of Significant Segment Expenses

The following table presents information about reported significant segment expenses:

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

Research and development external expenses

 

 

 

 

 

 

Iluzanebart

 

$

3,469

 

 

$

3,661

 

Small molecule TREM2

 

 

4,791

 

 

 

3,703

 

Research and development - other

 

 

1,439

 

 

 

981

 

Total research and development external expenses

 

 

9,699

 

 

 

8,345

 

General and administrative external expenses

 

 

2,356

 

 

 

2,221

 

Facilities, personnel-related, and other

 

 

11,414

 

 

 

10,849

 

Loss from operations

 

 

(23,469

)

 

 

(21,415

)

Other income (expense), net

 

 

1,056

 

 

 

1,475

 

Net loss

 

$

(22,413

)

 

$

(19,940

)